



There is a great need for pharmacogenetic biomarkers to individualize drug therapy, 
especially for therapies such as gemcitabine, which are associated with life threatening 
adverse events and are used in difficult-to-treat diseases such as pancreatic cancer. This 
study seeks to use a candidate gene, candidate single nucleotide polymorphism (SNP) 
approach to identify novel biomarkers for the development of neutropenia in patients 
treated with gemcitabine in the Cancer and Leukemia Group B (CALGB) study 80303. 
More than 180 candidate genes were identified, and 22 were selected for a pilot study. 
Using online bioinformatics resources, 370 candidate SNPs with putative functional 
effects were identified and tested for association using competing risks regression. Three 
SNPs from three candidate genes were found to have nominally significant p-values for 
association with grade 3 or 4 neutropenia in the study population: WWOX rs12373085 
(p=2.00E-04), CDA rs2072671 (p=0.025), and CYP1B1 rs162556 (p=0.025). Hypotheses 
for potential effects of these variant genotypes were proposed, but merit further 
validation. We conclude that this unique candidate gene, candidate SNP approach 
identified potential functional variants with nominally significant associations with the 
development of neutropenia in pancreatic cancer patients treated with gemcitabine, and 
may be a viable method to be applied to the full set of candidate genes. 
 
Introduction 
Pancreatic cancer causes an estimated 37,390 deaths per year in the US, and is the fourth 
leading cause of cancer-related death for both males and females. (1) Tumor resection 
remains the only curative treatment for pancreatic cancer, yet 80-85% of patients present 
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with unresectable disease. While adjuvant chemotherapy improves five-year overall 
survival, 80% of patients with resectable disease will relapse within two years. 
Chemotherapy improves response rates and overall survival in patients with locally 
advanced unresectable or metastatic disease, but median survival is only six months for 
patients with metastatic disease. (2,3)  
 
A mainstay of treatment for pancreatic cancer is the antimetabolite cytidine analog 
gemcitabine. (4) Hematologic toxicities have been reported in a large percentage of 
patients, with myelosuppression being the main dose-limiting toxicity. Neutropenia 
occurs in 61 percent of patients with pancreatic cancer, with 24 percent reporting grade 3 
or 4 neutropenia. (5) Recently, FOLFIRINOX, a combination of 5-fluorouracil, 
irinotecan, and oxaliplatin, has shown improved overall survival in patients with stage IV 
disease, but causes a higher incidence of adverse events compared to gemcitabine and 
therefore may not be an option for all patients. (6) In patients receiving gemcitabine, 
there is no method to predict who will experience myelosuppression, or to what degree. 
These adverse effects impact quality of life, as well as clinical outcome. Patients 
experiencing neutropenia must receive a reduced dose or delay treatment altogether, and 
these delays or reductions in chemotherapy represent missed opportunities to achieve 
optimal treatment efficacy. (7)  
 
Variability in response to chemotherapy in terms of both therapeutic efficacy and adverse 
effect profiles may be attributable to a number of factors, including environmental and 
clinical factors, but have also been shown to be influenced by genetics. For example, one 
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study demonstrated heritability for cytotoxicity of 5-fluorouracil and docetaxel using 
lymphoblastoid cell lines. (8) Currently, there are a small number of instances in which 
germline genetic variants are being used as pharmacogenetic biomarkers, to predict 
response or adverse effects of chemotherapeutic agents. The UGT1A1*28 allele was 
shown to be associated with development of neutropenia in patients receiving irinotecan. 
(9) Variants in TMPT associate with increased toxicities in patients receiving 
mercaptopurine. (10) Both of these findings have prompted the FDA to recommend 
genotyping for patients receiving these agents to improve the safety and efficacy of 
treatment.  There is a great need for more pharmacogenetic biomarkers to individualize 
drug therapy, especially for therapies such as gemcitabine, which are associated with life 
threatening adverse events. 
 
There are currently two major approaches used to identify genetic variants related to an 
outcome of interest, each with associated pros and cons. Genome-wide association 
studies (GWAS) involve assessing the entire genome without bias of current knowledge. 
This approach is useful for multigenic traits or identification of novel markers. However, 
the large number of comparisons made at the genome-wide level contribute to a large 
multiple testing correction burden for GWAS. These studies are costly to perform, and 
findings may be difficult to interpret. The second method, the candidate-gene approach, 
relies on a priori knowledge of the function of particular genes of interest. Since it is 
based on current knowledge of gene and polymorphism function, it may miss many real 
associations. It also has low predictive power for traits that are contributed to by multiple 
genes. However, this approach is low cost, with relatively easy to interpret and analyze 
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results since gene selection is hypothesis-driven. There is a lower multiple testing 
correction burden for candidate-gene studies since there are a limited number of 
comparisons made.  
 
Due to the advantages listed above, a candidate gene approach was chosen for this study. 
Further, we sought to strengthen the likelihood that variants identified for association 
with neutropenia are causal functional variants rather than simply tagging single 
nucleotide polymorphisms (SNPs) in linkage disequilibrium with the putative functional 
variant. Using a variety of online pharmacogenomics resources, a select group of 
candidate SNPs were chosen for testing in a population of cancer patients. Therefore, this 
study seeks to use a candidate gene, candidate SNP approach to identify novel 
biomarkers for the development of neutropenia in patients treated with gemcitabine in the 
Cancer and Leukemia Group B (CALGB) study 80303.  
 
Methods 
Clinical Trial and Patients 
CALGB 80303 was a double blind, placebo-controlled, randomized study of gemcitabine 
plus bevacizumab versus gemcitabine plus placebo in 602 patients with advanced 
pancreatic cancer. (11) Eligible patients had histologically or cytologically confirmed 
pancreatic adenocarcinoma not amenable to curative surgery, and had not received prior 
chemotherapy for metastatic disease. An Eastern Cooperative Oncology Group (ECOG) 
performance status of 0 to 2 and adequate bone marrow, renal, and hepatic function were 
required. Gemcitabine at 1,000 mg/m2 was given intravenously over 30 minutes on days 
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1, 8, and 15 of a 28-day cycle. Bevacizumab at 10 mg/kg or placebo was administered 
intravenously after gemcitabine on days 1 and 15 of each cycle. Treatment was 
discontinued for progressive disease, unacceptable adverse events, or patient withdrawal 
of consent. Dose modifications for gemcitabine were based on toxicities experienced 
within one day of treatment, as described previously. (11) There was no difference in the 
primary endpoint of overall survival between treatment arms. Statistically significant 
differences in grade 3 or 4 toxicity occurred only for hypertension and proteinuria.  
 
DNA Samples and Genotyping 
Germline DNA was collected prospectively for pharmacogenetic studies from blood 
samples from 338 patients who consented to pharmacogenetic analysis, as described 
previously. (12) More than 550,000 SNPs were genotyped in these samples using the 
Illumina HumanHap550v3 Genotyping BeadChip. Genotyping was conducted at the 
Center for Genomic Medicine, Riken Institute. Characteristics of study patients and 
patients with genotyping information are summarized in Table 1.  
 
Candidate Gene Selection 
Candidate genes were selected for inclusion using a variety of criteria. Genes related to 
the pharmacology of gemcitabine were included, as well as genes containing 
pharmacogenomic variants of interest for gemcitabine efficacy or toxicity as annotated in 
the Pharmacogenomics Knowledgebase (PharmGKB). (13,14) A literature search of 
gemcitabine-related toxicity, sensitivity, and efficacy was conducted. (15-27) Relevant 
genes were selected and annotated for number of appearances in the literature. Finally, 
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genes related to gemcitabine cytotoxicity in lymphoblastoid cell lines were selected. (28) 
A total of 183 genes comprised the final candidate gene list (Supplementary Table 1). 
The results of a pilot study using 22 genes chosen arbitrarily from this final candidate 
gene list are presented here. 
 
Table 1. Patient Demographics (12) 
Sample Size All patients (N=602) GWAS patients (N=338) 
Sex 
  Male 








  Mean (SD) 







Race, n (%) 
  White 
  Black 
  Asian 
  Native Hawaiian 
  American Indian 
  Multiple 

















Extent of disease, n (%) 
  Metastatic 







Prior radiotherapy, n (%) 
  No 







Performance status, n (%) 
  0 or 1 







Arm, n (%) 
  Placebo 







OS time, mo 
  Median 














Candidate SNP Selection 
Polymorphisms occurring in the genotyped CALGB 80303 data within10kb flanking 
regions of each candidate gene and with a minor allele frequency greater than five 
percent were identified. Candidate SNPs to test for associations in the study population 
were selected using a variety of online bioinformatics applications (Figure 1).  
Figure 1. Candidate SNP Selection  
 
RegulomeDB (http://www.regulomedb.org/) uses data from GEO, the ENCODE project, 
and published literature to annotate SNPs with known and predicted regulatory elements 
in the intergenic regions of the human genome. (29) Scores assigned to each SNP by 
RegulomeDB were recorded, and are representative of the level of evidence associated 
with regulatory elements for each SNP (Supplementary Table 2). SNPs with a 
RegulomeDB score less than or equal to four were selected. 
 
The National Institute of Environmental Health Sciences (NIEHS) SNP Functional 
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Prediction tool (http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm) is designed to predict 
the potential effects of alternative alleles of SNPs on biological function, including 
transcriptional regulation by alteration of transcription factor binding sites (TFBS); 
premature termination of amino-acid sequence by addition of stop codons; changing of 
splicing pattern or efficiency by disrupting splice sites or exonic splicing enhancers 
(ESE) or silencers (ESS); alteration of protein structures or properties by changing single 
amino acids or changing the frame of the protein-coding region; or regulation of protein 
translation by affecting microRNA (miRNA) binding affinity. (30) SNPs with predicted 
effects in each of these areas, except those predicted to be benign non-synonymous SNPs, 
were selected.  
 
The Phenotype-Genotype Integrator (PheGenI) (http://www.ncbi.nlm.nih.gov/gap/ 
PheGenI) is a tool that integrates phenotypic associations from GWAS studies using a 
variety of databases. (31) Each SNP was queried and any association results with clinical 
phenotypes, GWAS associations, or others, were selected regardless of p-value. 
 
Finally, each candidate gene was searched using the PharmGKB database. (14) SNPs 
from CALGB 80303 study data also appearing in the PharmGKB list of relevant 
pharmacogenomic variants for each gene were selected. 
 
Linkage disequilibrium (LD) among selected SNPs was found with the SNP Annotation 
and Proxy (SNAP) tool (http://www.broadinstitute.org/mpg/snap/), using an r2 threshold 
of 0.8 in the CEU 1,000 Genomes population. (32) A tagging SNP from each LD block 
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was chosen for association testing.  
 
Liver eQTLs 
Expression quantitative trait loci (eQTLs), are genomic loci that associate with gene 
expression levels. The eQTL variants may be located in non-coding regions but affect the 
expression of nearby gene sequences, and therefore play an important role in identifying 
associations between functional genomic variants and disease phenotypes. (33) Given the 
vital role of the liver in metabolism and excretion of medications, eQTLs identified in 
liver tissue are of particular pharmacogenomic interest. For this study, we queried liver 
eQTL data that was previously collected from postmortem tissue and resections from 
donor livers in 183 European Americans and 23 African Americans, as previously 
described. (34) A group of eQTLs in the 22 selected candidate genes were identified and 
tested for association with neutropenia in addition to the list of candidate SNPs. 
 
Statistical Analysis 
A competing risks regression model was used to test for association of candidate SNPs 
with the development of grade 3 or 4 neutropenia in the CALBG 80303 study population. 
The Kaplan Meier method was used to determine the probability of neutropenia over the 
treatment course. P-values for results of this pilot study were not corrected for multiple 
comparisons. All statistical analysis was performed by the CALBG Statistical Group at 






A total of 370 candidate SNPs from the 22 selected candidate genes were identified for 
testing in the study population, along with an additional 2281 SNPs identified in the liver 
eQTL data set, for a total of 2243 SNPs. Thirty-eight of the 370 candidate SNPs were 
also eQTLs. Of the 2243 SNPs identified, only 207 were present in the genotyped data 
set. Three SNPs from three candidate genes were found to have nominally significant p-
values for association with grade 3 or 4 neutropenia in the study population (Table 2). 
The SNP with the highest statistical significance was rs12373085 in WWOX (P=2.00E-
04). 
 







Kaplan-Meier analysis demonstrated a higher probability of developing neutropenia in 
patients who were homozygous or heterozygous with the variant allele of rs12373085 
versus the CC genotype (Figure 2a). The variant CC and AC genotypes of rs2072671 
were associated with a lower probability of neutropenia compared to the AA genotype 
(Figure 2b), while individuals with the TT or TC genotypes of rs162556 were more likely 
to develop neutropenia than those who were homozygous for CC (Figure 2c). There were 
rsid P value Chromosome Alleles Gene Annotation 
rs12373085 2.00E-04 16 C/T WWOX RegDB=4 
rs2072671 0.025 1 A/C CDA RegDB=4 
rs162556 0.025 2 C/T CYP1B1 RegDB=3a 
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no significant statistical associations with eQTLs from the selected candidate genes.  
 










As a result of this preliminary study of a novel candidate gene, candidate SNP method, 
three SNPs were identified to have nominally significant associations with development 
of neutropenia in patients with pancreatic cancer treated with gemcitabine. No previous 
evidence in the literature was found for potential clinical effects of WWOX rs12373085. 
WWOX encodes WW domain containing oxidoreductase, and is involved in regulation of 
protein degradation, transcription, and RNA splicing. It also functions as a tumor 
suppressor gene, including in pancreatic cancer tumors, and has been shown to increase 
cancer cell sensitivity to chemotherapy in vitro. (35,36) In a GWAS of the CALGB 
80303 study population for overall survival, other SNPs in WWOX were associated with 
decreased overall survival, although their precise molecular function is unknown. (12) 
We hypothesize that variant alleles of rs12373085 may increase expression of the tumor 
suppressor WWOX, resulting in longer survival and time on treatment, resulting in an 
increased likelihood of neutropenia.  
 
In contrast to the WWOX SNP, rs2072671 in CDA has been described previously in 
connection with efficacy and toxicity related to gemcitabine and cytarabine, which, like 
gemcitabine, is an antimetabolite cytidine analog. (37-42) CDA codes for cytidine 
deaminase, an enzyme involved with pyrimidine salvaging. Within the gemcitabine 
metabolism pathway, CDA functions to convert gemcitabine to its inactive uracil 
metabolite through deamination. Existing literature is conflicting in regard to the effect of 
CDA rs2072671 genotypes on the risk of neutropenia, however. A study of patients with 
locally advanced pancreatic cancer treated with gemcitabine by Motofumi, et al. showed 
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a lower risk of grade 3 or 4 neutropenia and increased response to gemcitabine therapy in 
patients with the wild-type AA genotype than those with the AC or CC genotypes. (41)  
Conversely, Farrell, et al. demonstrated an increased risk of grade 3 or 4 hematologic 
toxicity in pancreatic cancer patients treated with gemcitabine with the homozygous and 
heterozygous wild-type genotypes, AA and AC, compared to the homozygous variant CC 
genotype. (42) The results of the present study suggest a higher association with the 
development of neutropenia in patients with the wild-type AA genotype than the CC or 
AC genotypes. We hypothesize that CDA rs2072671 variant genotypes may increase 
expression or functionality of CDA, resulting in greater inactivation of gemcitabine and 
subsequent decreased risk of neutropenia. However, these findings merit further 
replication given the nominally significant association (p=0.025), as well as the 
conflicting data in the literature in which other clinical or genetic patient factors may 
influence the risk of toxicities.  
 
The final SNP associated with development of neutropenia was CYP1B1 rs162556. While 
a number of studies have investigated associations of this variant with the risk of lung, 
breast, and bladder cancer, no evidence exists associating this particular SNP with drug 
toxicity. (43-45) The nominal significance of the association with the risk of neutropenia 
(p=0.025) warrants further investigation before a functional correlation can be 
determined.  
 
This study is limited inherently by its reliance on current knowledge of gene and 
polymorphism function and drug pathways to identify candidate genes and SNPs, which 
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may result in missing genes and polymorphisms with real associations. The statistical 
power of this study was limited by its sample size. The three SNPs identified as a result 
of this study were associated with the development of neutropenia at only a nominally 
significant level, and were not corrected for multiple comparisons.  
 
In conclusion, this preliminary study of a novel candidate gene, candidate SNP method 
identified 370 candidate SNPs from a pilot sample of 22 candidate genes. Three 
nominally significant SNPs were found to be associated with the development of 
neutropenia in pancreatic cancer patients treated with gemcitabine. Therefore, we 
conclude that this approach is a viable method to be applied to the full set of candidate 
genes. Future directions should include correction of any statistical associations for 
multiple comparisons, replication of findings in other data sets of pancreatic cancer 
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Table 2. RegulomeDB Scores (29)  
1a eQTL + TF binding + matched TF motif + matched DNase Footprint + DNase peak 
1b eQTL + TF binding + any motif + DNase Footprint + DNase peak 
1c eQTL + TF binding + matched TF motif + DNase peak 
1d eQTL + TF binding + any motif + DNase peak 
1e eQTL + TF binding + matched TF motif 
1f eQTL + TF binding / DNase peak 
2a TF binding + matched TF motif + matched DNase Footprint + DNase peak 
2b TF binding + any motif + DNase Footprint + DNase peak 
2c TF binding + matched TF motif + DNase peak 
3a TF binding + any motif + DNase peak 
3b TF binding + matched TF motif 
4 TF binding + DNase peak 
5 TF binding or DNase peak 
6 other 
 
